Gallbladder Neuroendocrine Tumor and 177 Lu DOTATATE: High Somatostatin Receptor Expression Without Clinical Response.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40472258.
- Also identified by DOI 10.1097/RLU.0000000000006001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gallbladder neuroendocrine tumors (GB-NETs) are rare, accounting for <0.5% of all NETs, and little is known about somatostatin receptor expression (SSTR) and its response to SSTR-targeted treatment such as Lutetium-177 ( 177 Lu) DOTATATE. 68 Ga DOTATATE PET/CT is a valuable imaging modality for SSTR expression and 177 Lu DOTATATE treatment planning. We present a case of a 74-year-old man with recurrent WHO grade 3 GB-NET. 177 Lu DOTATATE failed to control hepatic metastases despite high DOTATATE uptake, which led to treatment discontinuation. This case highlights the fact that positive SSTR imaging in GB-NETs does not always lead to a favorable response to 177 Lu DOTATATE.
Medical subject headings
- Neuroendocrine Tumors
- Receptors, Somatostatin
- Octreotide
- Organometallic Compounds
- Gallbladder Neoplasms
- Gene Expression Regulation, Neoplastic